CTLA-4 Ribozyme for CAR-T Specificity and Safety
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies, particularly those using chimeric antigen receptors (CARs), face limitations in effectively targeting solid cancers due to immunological suppression around cancer cells, and existing methods to inhibit CTLA-4 often result in low specificity and adverse effects.
Innovation Solution
A recombinant vector incorporating a CTLA-4-targeting trans-splicing ribozyme expression cassette is used to deliver a chimeric antigen receptor, specifically inhibiting CTLA-4 on T cells and enhancing their targeting function, thereby improving anti-cancer therapy specificity and efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If CAR therapy is used to target cancer cells, then anti-cancer specificity is improved, but therapeutic effect is reduced due to immunological suppression around cancer cells
Solution Approach 1:
The patent introduces CTLA-4 as an intermediary mechanism that mediates the suppression of T cell activity by cancer cells. By targeting and inhibiting CTLA-4 expression, the therapy removes the inhibitory signal that prevents CAR-T cells from effectively attacking cancer cells, thereby resolving the contradiction between specificity and therapeutic effect.
Solution Approach 2:
The patent changes the expression level of CTLA-4 from high (suppressing T cell activity) to low or absent (allowing T cell activation). This parameter change in CTLA-4 expression level enables CAR-T cells to overcome immunological suppression and exert effective anti-cancer activity while maintaining specificity.
2Productivity
If CTLA-4 inhibition is applied to enhance T cell activity, then anti-cancer efficiency is improved, but toxicity to normal tissues increases due to low specificity
Solution Approach 1:
The patent applies local quality by using a ribozyme system that is activated specifically in the context of CAR-T cell engagement with cancer cells. The ribozyme is designed to be expressed and become active only when T cells are stimulated by cancer cell antigens, ensuring that CTLA-4 inhibition occurs locally at the tumor site rather than systemically, thus improving efficiency while reducing toxicity to normal tissues.
Solution Approach 2:
The patent introduces a dynamic control mechanism where the ribozyme expression and activity are regulated by T cell activation status. The system transitions from a static CTLA-4 inhibition approach to a dynamic one where inhibition is activated only when needed (upon cancer cell recognition), allowing the system to adapt and reduce harmful effects when not engaged with cancer cells.
3Reliability
If conventional CTLA-4 inhibition methods are used, then T cell activity is enhanced, but specificity is reduced leading to adverse effects
Solution Approach 1:
The patent uses the ribozyme as an intermediary tool that provides precise control over CTLA-4 inhibition. The ribozyme system acts as a mediator between T cell activation and CTLA-4 inhibition, ensuring that inhibition occurs only when T cells are specifically activated by cancer cell antigens, thereby maintaining both reliability of T cell activity and specificity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach effectively inhibits CTLA-4 on T cells, increasing anti-cancer specificity and efficiency while reducing toxicity to normal tissues, making it a promising gene-cell therapy for cancer treatment.
Implementation Method 1
a CTLA-4-targeting trans-splicing ribozyme expression cassette for delivery of chimeric antigen receptor
Data Source
AI summary
The present invention relates to a recombinant vector, characterized by including a cytotoxic T-lymphocyte-associated protein-4 (CTLA-4)-targeting trans-splicing ribozyme expression cassette for delivery of chimeric antigen receptor, wherein the expression cassette includes: (i) a CTLA-4-targeting trans-splicing ribozyme; and (ii) a polynucleotide encoding a chimeric antigen receptor ligated to the 3′ exon of the ribozyme. The present invention also relates to a transformed cell into which the recombinant vector is introduced, a ribozyme expressed from the recombinant vector, a retrovirus expressing the ribozyme, and a T cell treated with the retrovirus. Furthermore, the present invention relates to a pharmaceutical composition for preventing or treating cancers, in which the pharmaceutical composition includes the recombinant vector, the transformed cell, the ribozyme, the retrovirus, the T cell, or a combination thereof; and a method for treating cancers, in which the method includes administering, to an individual in need thereof, the recombinant vector, the transformed cell, the ribozyme, the retrovirus, the T cell, or a combination thereof. The recombinant vector of the present invention and the ribozyme expressed therefrom become a gene-cell therapy which inhibits CTLA-4 on T cells which has been an obstacle in conventional anti-cancer therapies and, at the same time, enables anti-cancer treatment, thereby allowing more effective anti-cancer effects to be anticipated. Such a gene-cell therapy results in decreased toxicity in normal tissues and thus exhibits increased effects in both therapeutic efficacy and safety, which enables it to be widely utilized in the field of gene therapy in the future.